| 11.36 0.11 (0.98%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.75 | 1-year : | 14.27 |
| Resists | First : | 11.77 | Second : | 12.22 |
| Pivot price | 11.48  |
|||
| Supports | First : | 11.05 | Second : | 9.19 |
| MAs | MA(5) : | 11.21 |
MA(20) : | 11.57 |
| MA(100) : | 11.53 |
MA(250) : | 10.5 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 20.2 |
D(3) : | 14.2 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 13.61 | Low : | 8.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VTRS ] has closed above bottom band by 39.3%. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.41 - 11.46 | 11.46 - 11.51 |
| Low: | 11.07 - 11.13 | 11.13 - 11.19 |
| Close: | 11.26 - 11.36 | 11.36 - 11.45 |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Mon, 22 Apr 2024
What You Need To Know About Viatris Inc.'s (NASDAQ:VTRS) Investor Composition - Yahoo Movies UK
Mon, 08 Apr 2024
Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential (NASDAQ:VTRS) - Seeking Alpha
Wed, 27 Mar 2024
Viatris Inc. (VTRS) R&D Event (Transcript) - Seeking Alpha
Mon, 11 Mar 2024
US FDA declines to approve Viatris's injection for multiple sclerosis - Reuters
Wed, 28 Feb 2024
Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 28 Feb 2024
Viatris Inc (VTRS) Meets 2023 Financial Targets and Sets Course for Continued Growth in 2024 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1,190 (M) |
| Shares Float | 1,180 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 83.3 (%) |
| Shares Short | 36,390 (K) |
| Shares Short P.Month | 42,520 (K) |
| EPS | 0.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.04 |
| Profit Margin | 0.3 % |
| Operating Margin | 13.6 % |
| Return on Assets (ttm) | 2.7 % |
| Return on Equity (ttm) | 0.2 % |
| Qtrly Rev. Growth | -1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 12.96 |
| EBITDA (p.s.) | 4.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2,800 (M) |
| Levered Free Cash Flow | 1,100 (M) |
| PE Ratio | 227.19 |
| PEG Ratio | -1.8 |
| Price to Book value | 0.66 |
| Price to Sales | 0.87 |
| Price to Cash Flow | 4.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|